ovarian%20mass
OVARIAN MASS
Ovarian cysts are typically noted after clinical screening, or as a result of exam for a suspected pelvic mass, or an incidental finding in investigations done for other reasons.
Most ovarian masses manifest with few or mild nonspecific symptoms.
Ovarian masses in women of reproductive age are mostly benign but the risk of malignancy increases with age.
Ovarian cysts in the prepubertal patients especially after the first week of life are abnormal and likely to be neoplastic. In adolescent patients, majority of ovarian masses are functional cysts.

Pharmacotherapy

Monophasic Combination Oral Contraceptives (COCs)

  • Studies suggested that expectant management is as effective as hormonal treatment for the resolution of functional ovarian cysts
  • Patients may be offered oral contraceptives (OCs) if they are seeking contraception
  • Estrogen/progestogen therapy may be useful in patients with anovulatory cycles who need OCs to induce the next period
  • Many monophasic combination oral contraceptives are available. Please see the latest MIMS for specific formulations
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
03 Apr 2019
The sodium‐glucose‐cotransporter‐2 inhibitor empagliflozin yields beneficial effects on weight anthropometric parameters and body composition—including weight, body mass index, waist and hip circumference, and total body fat—that are greater than those achieved with metformin in overweight and obese women with polycystic ovary syndrome (PCOS), a study has shown.
Stephen Padilla, 03 Apr 2019
The risk of miscarriage is lowest at age 27 years but increases with older age and by up to four times after three consecutive previous miscarriages, according to a Norway study. This risk is also associated with earlier pregnancy complications, including stillbirth, preterm delivery and gestational diabetes.
Pearl Toh, 08 May 2019
Continuous chemotherapy confers better survival and quality of life than intermittent scheduling in patients with advanced breast cancer, according to the Stop&Go study presented at EBCC 2019.